Federated Hermes’s Genocea Biosciences, Inc. GNCA Stock Holding History

Federated Hermes’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-905	Closed	-$1K	–	2366
2022 Q1	$1K	Sell	905 -132	-13%	-$144	﹤0.01%	2163
2021 Q4	$1K	Hold	1,037	–	–	﹤0.01%	2191
2021 Q3	$2K	Buy	+1,037	New	+$2.04K	﹤0.01%	2119
2019 Q3	–	Sell	-340	Closed	-$1K	–	2370
2019 Q2	$1K	Sell	340 -1	-0.3%	-$5	﹤0.01%	2152
2019 Q1	$2K	Hold	341	–	–	﹤0.01%	2087
2018 Q4	$1K	Hold	341	–	–	﹤0.01%	2174
2018 Q3	$2K	Hold	341	–	–	﹤0.01%	2176
2018 Q2	$2K	Hold	341	–	–	﹤0.01%	2129
2018 Q1	$3K	Hold	341	–	–	﹤0.01%	2049
2017 Q4	$3K	Buy	341 +182	+114%	+$1.83K	﹤0.01%	2059
2017 Q3	$2K	Sell	159 -27	-15%	-$1.02K	﹤0.01%	2067
2017 Q2	$8K	Buy	+186	New	+$8.96K	﹤0.01%	1879

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Federated Hermes's GNCA Position: Q2 2022 in Review

Federated Hermes sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 905 shares — an estimated $1K sold.

Federated Hermes first reported a position in GNCA in Q2 2017 and held it in 12 quarters. The position peaked at $8K in Q2 2017. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Federated Hermes reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Federated Hermes sold 905 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $1K.
Federated Hermes first reported a position in Genocea Biosciences, Inc. in Q2 2017 and held it in 12 quarters.
Federated Hermes's Genocea Biosciences, Inc. position peaked at $8K in Q2 2017.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.